Nonprofits, scientists, governmental organizations, and the rare disease drug development industry have long cited 7,000 as the average number of rare diseases in the world. But a new analysis shows there are as many as 10,867 rare diseases globally. And that…
News
After the success of its virtual event last year, the Foundation for Sarcoidosis Research (FSR) is gearing up to once again host an online summit for all those impacted by sarcoidosis. The “Third Annual Global Virtual Patient Summit: Unveiling Possibilities” is set for July 30–31. Billed as the…
The Foundation for Sarcoidosis Research (FSR) has launched the FSR Global Sarcoidosis Clinic Alliance, a hub of clinics and hospitals around the world to advance care and research in sarcoidosis. Through engagement and education of both patients and clinicians, the initiative seeks to improve the lives of people with…
XTMAB-16, Xentria‘s investigational antibody-based therapy for treating sarcoidosis, was able to reduce the formation of granulomas — the abnormal clumps of immune cells that mark the disease — in a patient-derived cell model of granuloma, the company reported. The data were presented in a poster titled “XTMAB-16…
The National Organization for Rare Disorders’ (NORD) “Living Rare, Living Stronger Patient and Family Forum” is back in person on June 26 for a day of learning and networking in Cleveland, Ohio. The event, which brings together the rare disease community, will take place at the InterContinental Cleveland Conference…
Children living in the same household with adults who work in mineral dust-releasing jobs may have an increased risk of developing sarcoidosis, according to a small study. The findings suggest that indirect exposure to potentially harmful minerals — and specifically, inhaled mineral particles — through co-habitation with adults working…
African Americans with advanced-stage pulmonary sarcoidosis who are taking Acthar Gel (repository corticotropin injection) may see their symptoms ease and be able to reduce the use of other medications, according to new findings. The findings were pulled from a new subgroup analysis of a real-world study that…
aTyr Pharma is launching a Phase 3 clinical trial to evaluate the safety and effectiveness of efzofitimod (ATYR1923) in people with pulmonary sarcoidosis. Expected to begin later this year, the primary goal of the study — dubbed EFZO-FIT — will be a reduction in therapeutic corticosteroids, which…
A rare occurrence of sarcoidosis in male breast tissue was observed in an American man, according to a recent case report. The report, “A Rare Case of Sarcoidosis Involving Male Breast Tissue,” was published in the Cureus Journal of Medical Science. Sarcoidosis is characterized by…
A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ultimately brought the group of eight by car to temporary accommodations in neighboring Poland last month was physically and emotionally difficult,…
Recent Posts
- Autoimmune diseases tied to higher sarcoidosis risk, new study finds
- Atyr to discuss efzofitimod’s future with FDA after Phase 3 sarcoidosis trial
- How do you celebrate Autoimmune Awareness Month?
- New congressional caucus to advocate for sarcoidosis research, funding
- Free virtual conference aims to empower sarcoidosis community
- The best advice I ever got for dealing with a rare disease
- Sarcoidosis and ILD burden rising globally, new analysis finds
- At high dose, brepocitinib eases symptoms of sarcoidosis affecting skin
- Patients and healthcare providers should approach AI with caution
- New AI model predicts sudden cardiac death risk better in cardiac sarcoidosis